Guidant to apply for new ICD (implantable cardioverter defibrillator) indication
This article was originally published in Clinica
Executive Summary
Guidant plans to apply to the US FDA to expand the use of its implantable cardioverter defibrillators (ICDs) to include their use in patients at risk from sudden unexplained death syndrome (SUDS). The company's decision is based on results from the DEBUT (Defibrillator vs Beta-blockers for Unexplained Death in Thailand) study, which showed that ICDs were better than drugs in saving lives of people with SUDS who have no structural heart disease and a normal ejection fraction.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.